ENTA - Enanta Pharmaceuticals, Inc.
| Previous Close | 90.34 |
| Open | 90.81 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 88.38 - 92.42 |
| 52 Week Range | 38.40 - 127.77 |
| Volume | 182,549 |
| Avg. Volume | 290,379 |
| Market Cap | 1.787B |
| Beta | 1.30 |
| PE Ratio (TTM) | 23.33 |
| EPS (TTM) | 3.95 |
| Earnings Date | May 7, 2018 - May 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 103.60 |
- Thomson Reuters StreetEvents•8 hours ago
Edited Transcript of ENTA earnings conference call or presentation 7-Aug-18 8:30pm GMT
Q3 2018 Enanta Pharmaceuticals Inc Earnings Call
- InvestorPlace•9 days ago
Why Enanta Stock Is Still a Strong Buy With Huge Upside
Enanta Pharmaceuticals (NASDAQ:ENTA) has been in the news recently. Before I get around to what’s been happening with ENTA stock recently, it may help to get a broader understanding of how the company operates and what exactly it does. What used to be a fairly typical model, where you discover a drug, run it through the various drug trials, build a marketing plan and sell the drug, has now become much more focused.
- Zacks•14 days ago
Enanta Pharmaceuticals (ENTA) Q3 Earnings and Revenues Top Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 1.04% and 1.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•14 days ago
Enanta Pharmaceuticals: Fiscal 3Q Earnings Snapshot
On a per-share basis, the Watertown, Massachusetts-based company said it had profit of 97 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- Business Wire•14 days ago
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018
Webcast and Conference Call today at 4:30 p.m. ET
- Zacks•20 days ago
Why Earnings Season Could Be Great for Enanta Pharmaceuticals (ENTA)
Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Business Wire•last month
Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30, 2018
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2018, after the U.S. markets close on August 7, 2018. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline. To participate in the live conference call, please dial (855) 840-0595 in the U.S. or (518) 444-4814 for international callers.
- Zacks•2 months ago
Achieve Life Sciences' Shares Rise on Positive Clinical Data
Achieve Life Sciences' (ACHV) pipeline candidate, cytisine, evaluated for smoking cessation, shows no significant interaction with other medication.
- InvestorPlace•2 months ago
2 Stable and 2 Speculative Biotech Stocks to Buy
Biotech stocks represent a peculiar conundrum. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. Thus, creating a list of biotech stocks to buy will always be a tough challenge.
- Business Wire•2 months ago
Enanta Pharmaceuticals Recognizes the 1st International NASH Day
Enanta Pharmaceuticals, Inc., (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, is proud to support the 1st International NASH Day taking place today. This is a ground-breaking event organized by the NASH Education Program and its benefactors and supporters around the world. NASH is expected to become the #1 cause of liver transplant by 2020 in the United States, and its prevalence is projected to increase globally in association with obesity and type 2-diabetes.
- ACCESSWIRE•2 months ago
Today's Research Reports on Stocks to Watch: Enanta Pharmaceuticals and Vascular Biogenics
NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Enanta Pharmaceuticals as well as Vascular Biogenics were two stocks in the biotech arena making big moves in Wednesday's trading session. Enanta climbed higher ...
- Zacks•3 months ago
Why Enanta Pharmaceuticals (ENTA) Could Shock the Market Soon
Although overlooked by the investors, Enanta Pharmaceuticals (ENTA) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.
- Business Wire•3 months ago
Enanta Pharmaceuticals to Present at the NASDAQ 38th Investor Conference Presentation to be Webcast on June 12 at 9:30 A.M. GMT
Enanta Pharmaceuticals, Inc., (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, President and Chief Executive Officer will make a presentation followed by a question and answer session at the NASDAQ 38th Investor Conference on June 12 at 9:30 a.m. GMT in London. A live webcast of the presentation will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com.
- Zacks•3 months ago
Bayer's Generic Competition, Pipeline Setback Issues Remain
Generic threats/competition for many of its products remain a concern for Bayer (BAYRY).
- GlobeNewswire•3 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant S.A, 8point3 Energy Partners LP, Flexion Therapeutics, and Enanta Pharmaceuticals — New Research Emphasizes Economic Growth
NEW YORK, May 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Assembly ...
- Zacks•3 months ago
Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y
Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.
- Market Realist•3 months ago
Analysing NVR, DPZ, ENTA And QLYS Stocks
NVR’s (NVR) net income has grown at a 3-year and 5-year average of 24% and 24.3% respectively. The company’s pre-tax margin grew from 9.9% in 2013 to 13.4% in 2017. The stock prices have beaten the residential construction industry between 2013 and 2017. The stock was beaten in 2013 and 2016 by the S&P 500. The market cap had gained 188% between 2013 and 2017.
- Market Realist•3 months ago
Total Returns and Sector Exposure for Growth Indexes—Continued
The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively. They have five-year annualized returns of 15% and 12.7%, respectively. They have YTD (year-to-date) returns of 5.4% and 6.1%, respectively.
- Zacks•3 months ago
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.
- Zacks•3 months ago
Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.
- Zacks•3 months ago
Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion
Zoetis (ZTS) inks a definitive deal to acquire Caifornia-based Abaxis, for $83 per share in cash or a total of $2 billion.
- Zacks•3 months ago
Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
- Zacks•3 months ago
Roche's Actemra Gets FDA Nod for Subcutaneous Formulation
FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ENTA earnings conference call or presentation 8-May-18 8:30pm GMT
Q2 2018 Enanta Pharmaceuticals Inc Earnings Call
